Christine Günther, MD, PhD
Partner
Christine Günther is a Senior Executive Manager and Biotech Entrepreneur with extensive experience in cell and gene therapy and clinical medicine. She focuses on translating advanced therapy concepts into clinical applications and has broad expertise across CMC, regulatory strategy, and clinical development.
Christine spent over 12 years as CEO of APCETH (Munich, Germany) - now Minaris Advanced Therapies - leading the company from its foundation to its acquisition by Hitachi Chemical in 2019. During this period, she established two GMP manufacturing facilities, advanced the first genetically modified mesenchymal cell therapy for cancer into clinical development, and built APCETH into a profitable CDMO.
From 2021 to 2025, she served as Entrepreneur-in-Residence at Evotec, where she led key initiatives to develop the company’s cell therapy strategy with a particular focus on the iPSC-based platform. She subsequently became Managing Director of the GMP Cell Factory in Italy, leading its transition to clinical-stage readiness.
Christine holds a medical degree from LMU Munich and a PhD in experimental hematology. She worked as a Senior Attending Physician (Oberärztin) in internal medicine and hematology/oncology, specializing in stem cell transplantation and inflammation & immunity. She has been contributing to multiple taskforces and advisory roles.
Her clinical experience shapes her commitment to advancing transformative therapies and connecting innovation with real patient needs.
Chief Technology Officer (part time)
Private company (Zürich)
Regenerative medicine
Elected Member of the Fraunhofer-Gesellschaft
Member of the Board of the Institute for Biomedical Technology (Saarbrücken)